Veryan Medical Ltd.
This article was originally published in Start Up
Executive Summary
While the incorporation of drugs has radically reduced restenosis in coronary stents, it remains a serious issue in other vascular devices. Veryan Medical Ltd. thinks that the problem lies in the limitations of 2-D cylindrical devices to accommodate the natural, 3-D flow of blood. The company is building devices that replicate the swirling flow of blood through the vasculature. That spiral flow flushes out areas of stagnation and prevent the formation of intimal hyperplasia and restenosis.
You may also be interested in...
Edwards: Battling the Innovator's Dilemma
Having built a franchise serving cardiac surgeon, Edwards is looking to maintain its market leadership by both expanding into peripherals and embracing interventionalists.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.